Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    34
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA02 CIPRODAR G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 392,402 L.L
J01MA02 CIPROFAR G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 241,892 L.L
J01MA02 CIPROLON 500 G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 295,645 L.L
J01MA02 CIPROMAX G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 392,402 L.L
J01MA02 CIPROMID G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 331,929 L.L
J01MA02 CIPROPHARM G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 354,774 L.L
J01MA02 ESTECINA 500MG G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 618,168 L.L
A07EC02 SALOFALK B Mesalazine - 500mg 500mg Tablet, enteric coated 2,874,479 L.L
J01MA02 LADININ G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 572,393 L.L
A07EC02 SALCROZINE G Mesalazine - 500mg 500mg Tablet, gastroresistant 2,013,076 L.L
J01MA02 SUPERFLOX G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 458,250 L.L
M01AE02 PROXEN 500 B Naproxen - 500mg 500mg Tablet, film coated 841,245 L.L
M01AE02 NOPAIN DS G Naproxen (sodium) - 500mg 500mg Tablet, film coated 235,172 L.L
C03CA01 LASIX B Furosemide - 500mg 500mg Tablet 1,454,038 L.L
A07EC02 ASACOL B Mesalazine - 500mg 500mg Suppository 1,703,992 L.L
M01AE02 ANODYNE 500 G Naproxen - 500mg 500mg Suppository 342,680 L.L
A07EC02 SALOFALK 500 B Mesalazine - 500mg 500mg Suppository 677,297 L.L
A07EC02 SALCROZINE G Mesalazine - 500mg 500mg Suppository 576,508 L.L
L04AA06 CELLCEPT B Mycophenolate mofetil - 500mg 500mg Tablet 6,083,575 L.L
L04AA06 IMUNOCELL G Mycophenolate mofetil - 500mg 500mg Tablet, film coated 3,791,428 L.L
L04AA06 MMF G Mycophenolate mofetil - 500mg 500mg Tablet, coated 4,087,969 L.L
J01DB01 KEFLEX B Cefalexin (monohydrate) - 500mg 500mg Capsule 659,123 L.L
N02BE01 EFFERALGAN B Paracetamol - 500mg 500mg Tablet, effervescent scored 129,009 L.L
N02BE01 PANADOL ACTIFAST B Paracetamol - 500mg 500mg Tablet, film coated 159,917 L.L
N02BE01 DOLIPRANE B Paracetamol - 500mg 500mg Tablet 120,946 L.L
N02BE01 DOLIPRANE B Paracetamol - 500mg 500mg Tablet 120,946 L.L
J01MA12 TAVANIC B Levofloxacin - 500mg 500mg Tablet, film-scored 1,150,329 L.L
N02BE01 PANADOL ADVANCE B Paracetamol - 500mg 500mg Tablet, film coated 438,093 L.L
J01MA12 FLOBIOX G Levofloxacin - 500mg 500mg Tablet, film coated 629,686 L.L
N02BE01 PANADOL ADVANCE B Paracetamol - 500mg 500mg Tablet, film coated 137,072 L.L
    ...
    34
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025